latest news releases from the newsroom
uBid.com Holdings, Inc. Acquires Auction Assets of Bidville, Inc.
BOCA RATON, Fla., July 27, 2006 (PRIMEZONE) -- Bidville, Inc. (Pink Sheets:BVLE), an innovative and growing online consumer marketer, announced today that it has completed the sale of its online auction business, including the Bidville.com name, URL and website to uBid.com Holdings, Inc. (OTCBB:UBHI), the owner and operator of uBid.com. The sale is part of a broad strategic restructuring and shift for focus of Bidville which earlier this month acquired DigiKidz, Inc., a rapidly growing online and retail channel producer and marketer of children's personalized DVDs.
Skins Inc. to Debut at WSA
NEW YORK, July 27, 2006 (PRIMEZONE) -- Skins Inc. ("Skins") (OTCBB:SKNN), an emerging footwear company, is pleased to announce the brand's debut at WSA -- Las Vegas' Shoe Show from August 1 - 4, 2006. WSA hosts two premier footwear events annually serving the $47 billion footwear market -- the world's largest.
Vertical Computer Systems, Inc.
Vertical Computer Systems Adds Constructive Key Management to Its Security Solution Software Offerings Through an Agreement With TecSec
FORT WORTH, Texas, July 27, 2006 (PRIMEZONE) -- Vertical Computer Systems, Inc. (OTCBB:VCSY) announced today that it has entered into an agreement with TecSec, Incorporated (TecSec) to market TecSec's CKM(r) or Constructive Key Management(r) products, a standards-based and patented key management encryption system. Under the agreement, VCSY may offer CKM products in a bundled solution with the products marketed by VCSY and its subsidiaries, including emPath(r) (HRMS), SiteFlash, StatePointPlus, and ImmuneApp.
Hugin Ad Hoc Announcement According to Sec. 15 WpHG: Pure Forecast: MorphoSys AG: MorphoSys Raises Financial Guidance for 2006
MARTINSRIED, Germany, July 27, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) today provided an increased guidance for the financial year 2006. On the basis of new collaborations and the expansion of the collaboration with Novartis, an outperformance of revenues versus guidance was identified for the current year in the amount of up to EUR 2 million, which could increase 2006 revenues from EUR 50 million to up to EUR 52 million. Scope for reduction on expense guidance for the full year was also given, with a decrease in expenses of up to EUR 3 million, which could decrease expenses for the full year 2006 from EUR 49 million to EUR 46 million. The impact of these changes could result in earnings before interest and taxes (EBIT) of up to EUR 6 million. Future Company financial guidance will be provided on an EBIT basis only. For comparative purposes, non-operating expenses are estimated at approx. EUR 1 million, resulting in a potential net profit of up to EUR 5 million (original guidance: EUR 1 million).